Inventor:

William D. Huse

Serial No.:


08/790,540

Filed:

January 30, 1997

Page 2

identity with that] shown in Figure 1A (SEQ ID NO:2), said variable region amino acid sequence having a framework sequence having 88% or greater identity with the framework sequence of SEO ID NO:2, and at least one LM609 CDR-grafted light chain polypeptide comprising a variable region amino acid sequence [having greater than 79% identity with that] shown in Figure 1B (SEQ ID NO:4), said variable region amino acid sequence having a framework sequence having 79% or greater identity with the framework sequence of SEO ID NO:4, or a functional fragment thereof, said LM609 CDR-grafted antibody or functional fragment thereof having integrin  $\alpha_{\nu}\beta_{3}$  binding activity, integrin  $\alpha_{\nu}\beta_{3}$  binding specificity or integrin  $\alpha_{\nu}\beta_{3}$ -inhibitory activity, wherein said variable region amino acid sequences encoding said heavy and light chain polypeptides are non-mouse sequences.



4. (Three Times Amended) The nucleic acid of claim 3, wherein said fragment further comprises a nucleic acid encoding a nucleotide sequence, or a modification [thereof that] of said nucleotide sequence wherein said modification does not change the encoded amino acid sequence, as the variable region of said LM609 CDR-grafted heavy chain polypeptide (SEQ ID NO:1).





Inventor:

William D. Huse

Serial No.:

08/790,540

Filed:

January 30, 1997

Page 3

6. (Three Times Amended) A nucleic acid encoding a LM609 CDR-grafted light chain polypeptide comprising a LM609 CDR-grafted light chain variable region nucleotide sequence, or a modification [thereof that] of said nucleotide sequence wherein said modification does not change the encoded amino acid sequence, shown in Figure 1B (SEQ ID NO:3) or a fragment thereof.

2/3

7. (Three Times Amended) The nucleic acid of claim 6, wherein said fragment further comprises a nucleic acid encoding a nucleotide sequence, or a modification [thereof that] of said nucleotide sequence wherein said modification does not change the encoded amino acid sequence, as the variable region of said LM609 CDR-grafted light chain polypeptide (SEQ ID NO:3).



9. (Three Times Amended) A nucleic acid encoding a LM609 CDR-grafted antibody heavy chain polypeptide comprising a nucleotide sequence encoding a LM609 CDR-grafted heavy chain variable region amino acid sequence having [greater than] 88% or greater identity with that shown in Figure 1A (SEQ ID NO:2) or fragment thereof, wherein said variable region amino acid sequence encoding said heavy chain polypeptide is a non-mouse sequence and wherein said nucleic acid encodes a heavy chain polypeptide of an antibody having integrin  $\alpha_{\nu}\beta_{3}$  binding activity, integrin  $\alpha_{\nu}\beta_{3}$  binding specificity, or integrin  $\alpha_{\nu}\beta_{3}$ -inhibitory activity.

Inventor:

William D. Huse

Serial No.:

08/790,540

Filed: Page 4

January 30, 1997

25

12. (Three Times Amended) A nucleic acid encoding a LM609 CDR-grafted antibody light chain polypeptide comprising a nucleotide sequence encoding a LM609 CDR-grafted light chain variable region amino acid sequence having [greater than] 79% or greater identity with that shown in Figure 1B (SEQ ID NO:4) or fragment thereof, wherein said variable region amino acid sequence encoding said light chain polypeptide is a non-mouse sequence and wherein said nucleic acid encodes a light chain polypeptide of an antibody having integrin  $\alpha_{\nu}\beta_{3}$  binding activity, integrin  $\alpha_{\nu}\beta_{3}$  binding specificity, or integrin  $\alpha_{\nu}\beta_{3}$ -inhibitory activity.

26

15. (Three Times Amended) A LM609 CDR-grafted heavy chain polypeptide comprising a variable region amino acid sequence having [greater than] 88% or greater identity with that shown in Figure 1A (SEQ ID NO:2) or functional fragment thereof, wherein said variable region amino acid sequence encoding said heavy chain polypeptide is a non-mouse sequence and wherein an antibody comprising said heavy chain polypeptide has integrin  $\alpha_{\rm V}\beta_3$  binding activity, integrin  $\alpha_{\rm V}\beta_3$  binding specificity, or integrin  $\alpha_{\rm V}\beta_3$ -inhibitory activity.